Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
News Release Digital Asset Direct

The Energy Sector XLE Fund: Simplifying the Energy Sector Landscape

Select Sector SPDR

In the intricate web of the investment landscape, the Energy Select Sector SPDR Fund (XLE) is an interesting option for those looking to engage with the energy sector. By aiming to reflect the outcomes of the Energy Select Sector Index, XLE provides access to a portfolio that encompasses some of the largest U.S. energy companies. The realm of energy is marked by its essential role in global infrastructure and its susceptibility to shifts in technological innovation and geopolitical climates. XLE distinguishes itself by offering a streamlined avenue to participate in this pivotal sector. The portfolio consists of all the energy companies in the S&P 500 and offers a diverse selection of companies in the oil, gas, consumable fuels, and energy equipment and services industries. Opting for passive management, XLE provides the advantage of exposure across a wide range of firms within the energy domain, coupled with the diversification benefits a portfolio of companies can provide. This strategy is especially valuable in an industry that faces continuous change and innovation. A glance at XLE's portfolio* reveals a well-rounded mix of entities that exemplify the diversity and significance of the U.S. energy sector. Exxon Mobil: 23.85% Chevron: 16.87% EOG Resources: 4.93% Marathon Petroleum: 4.50% ConocoPhillips: 4.49% Schlumberger: 4.42% Phillips 66: 4.37% Williams Companies: 4.09% ONEOK: 3.96% Valero Energy: 3.52% In a world where the energy narrative is frequently dominated by discussions of sustainability and market shifts, XLE represents a focused approach to engaging with the energy sector. With over $37 billion in assets and maintaining a low total expense ratio of 0.09%**, XLE proves to be a considerate choice for those wishing to explore the energy market without the overhead of managing individual stock selections. Looking ahead, the Energy Select Sector SPDR Fund (XLE) remains a relevant and accessible option for investors interested in the energy sector. By including a selection of leading companies and reflecting the broader market, XLE provides an opportunity to gain exposure to the dynamics shaping our energy future. The Energy Select Sector SPDR Fund (XLE) welcomes those intrigued by the energy sector to discover the breadth and depth of opportunities it holds, through a lens that balances insight with accessibility. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 8/31/24 subject to change **Ordinary brokerage fees apply DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007799 EXP 10/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

September 12, 2024 05:00 AM Eastern Daylight Time

AI Software Company Amesite Posts Its Largest Win In Community College Deal And Makes Natural Pivot To On-The-Job AI Support For Healthcare

Benzinga

By Meg Flippin, Benzinga Education is getting an overhaul thanks to artificial intelligence (AI) and companies like Amesite (NASDAQ: AMST). The Detroit-based AI software company develops products and platforms to improve online learning. Leveraging GPT-4, the AI system powering Bing and ChatGPT Plus, Amesite says that online courses can be added quickly, programs are adaptable and users stay engaged. That approach to learning is getting attention from educators, particularly with community colleges around the country. Maricopa Corporate College (MCOR) is part of the Maricopa Community College District (MCCCD), Arizona’s largest workforce developer. MCOR recently signed an agreement with Amesite. Expanding Its College Reach Amesite just inked a multiyear deal to provide programs through MCOR, to provide AI-based online training and development. With roughly 140,000 students, MCCCD is Arizona’s largest workforce developer, playing a central role in charting the future of the Greater Phoenix region. The school system produces the second-largest number of college graduates in Arizona and creates one out of every 28 jobs in Maricopa County, adding $7.9 billion to the economy. This exclusive agreement marks the biggest customer yet for the AI software company. It's exactly the type of enterprise Amesite is targeting. With a focus on community colleges, the company now counts seven institutions as customers offering students and faculty the Amesite LCE platform. Installations span the United States, with colleges in Alabama, Illinois, Louisiana, South Carolina, Tennessee, West Virginia and now, Arizona. Collectively, colleges that have chosen Amesite train over 200,000 learners each year, reports the company. "Our AI-powered solution enables professional learners to get information – and support – in real-time,” said Dr. Ann Marie Sastry, CEO of Amesite, in a press release announcing the deal with Maricopa. “We have long believed that AI-assisted professional training would replace traditional training and are pleased to see our solutions gaining acceptance, now with larger colleges. We are especially pleased to be the first to provide the right tools in this market." In Amesite’s vision for education and upskilling, learners aren’t taught in isolated silos but rather are part of a larger learning community. V6, the latest version of its learning platform, is the fruition of that AI-driven vision. It offers capabilities such as learning and creative assistants, and supports educational games, interactive learning experiences and other learning incentives to keep students engaged. V6 can integrate thousands of application programming interfaces (API), which means it works with most companies’ and schools’ programs. Setting Its Sights On Larger Markets But educating the workforce of tomorrow through community colleges isn’t the only thing Amesite is doing with its advanced AI. The company’s infrastructure and capabilities in AI programming can be easily deployed to provide on-the-job apps for different industries, including healthcare – specifically, the 5.2 million nurses in the U.S. who could benefit from some AI technology. In the spring, Amesite launched NurseMagic™, a proprietary AI app designed for nurses. With it, nurses can write nursing notes instantly, quickly translate medical terms into easy-to-understand language, create work emails, assist nurses in talking to patients with compassion, coach nurses on taking effective breaks during the day, provide key information about medications and collect instant feedback. It makes sense that Amesite would want to set its sights on nurses. Despite the over five million of them in the workforce, America is facing a shortage that’s projected to grow, not to mention the high burnout rate for this profession. Introducing technology that makes their lives easier not only improves their careers but saves hospitals and healthcare systems money. After all, burnout can cost a hospital $16,736 per nurse per year through retention challenges, sick days and training new replacement nurses. “Launching apps enables us to directly reach much larger audiences. We want to equip every nurse on the planet with tools that deliver immediate, qualified information and address the demands on their time while leveraging their expertise,” said Sastry at the time. A Continued Focus On Innovation Not one to rest on its laurels, since rolling out NurseMagic, Amesite has been adding to the app’s capabilities, working hard to ensure it maintains its competitive lead and becomes the leading app for nurses. Some of those enhancements include the ability to build and update a resume, write cover letters for job applications, create text that improves a nurse’s social profile on LinkedIn and other sites and create replies to employers that highlight the applicant’s strengths. With those enhancements, Amesite says it’s helping the 35% of nurses who indicate they may look for a new job in the next year. The app is also capable of creating nursing notes, a requirement for professionals ranging from CNAs and LPNs to APRN-CNPs and NPs which Amesite says takes up 40% of nurses’ time. The company also recently added the ability to upload and store study materials – including pdfs and video and audio files – to instantly create transcripts, summaries and even quizzes and flashcards, based on the material. Proof Is In The Accuracy All these enhancements to NurseMagic are only as good as the AI behind it and Amesite has that covered as well. The company reports the foundational model that powers NurseMagic achieved a 93% accuracy rate when tested with questions from two leading NCLEX prep providers’ test banks. The NCLEX exam is a standardized exam developed by the National Council of State Boards of Nursing (NCSBN) that nursing graduates must pass to obtain their nursing licenses in the United States and Canada. Accuracy is essential for the growing number of nurses using the app. In June, the app was released in beta. Within a week of the release, close to 1,200 individuals completed an onboarding survey and registered as users of NurseMagic. Since then, usage has continued to gain momentum. At last check, NurseMagic has users from all 50 U.S. states and six nations. User growth continued to expand rapidly after launch, up 830% month-over-month from June to July. It also has the support of some popular influencers in the nursing community, including Paige Slayton, a nurse influencer engaged by Amesite, with over 900,000 followers. "This is the fastest growth in usership that we have ever seen with any of our products,” said Sastry. “We are excited to be delivering a vital and useful tool to the largest segment of healthcare professionals and believe that NurseMagic TM will create a positive impact in healthcare and strong, sustainable revenue growth for Amesite." From education to healthcare, Amesite's AI-powered learning platform is empowering countless people and making professionals’ lives much easier. With a model that can be replicated for different industries and markets, Amesite is carving out its path to stand out in the AI-powered learning of tomorrow. Featured photo by Hush Naidoo Jade Photography on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 11, 2024 08:30 AM Eastern Daylight Time

Image

TRON, Tether, and TRM Labs Establish First-Ever Private Sector Financial Crime Unit to Combat Crypto Crime

TRON DAO

Singapore — September 10, 2024 — TRON, Tether, and TRM Labs today announced they have joined forces to establish the T3 Financial Crime Unit (T3 FCU), a first-of-its-kind initiative aimed at facilitating public-private collaboration to combat illicit activity associated with the use of USDT on the TRON blockchain. This novel collaboration brings together the anti-financial crime expertise of TRM Labs, a leading blockchain intelligence firm; the technical expertise of TRON, a leading global blockchain and DAO; and external investigations team at Tether, the largest company in the digital asset industry, to create a safer and more secure crypto community for all. In the weeks since launch, the initiative, in collaboration with law enforcement, facilitated the freezing of over USDT 12 million in funds associated with a blackmail scam, an investment fraud scheme, and others. Police are aware of at least 11 victims impacted by the scams and expect to identify additional victims as the investigations unfold. Stablecoins like USDT serve as the backbone of the digital asset industry, providing a stable store of value and enabling seamless movement of funds between platforms. With over $117 billion USD in market capitalization and more than 50% of its circulating supply running on the TRON blockchain, USDT is integral to facilitating transactions and liquidity. However, the same features that make USDT on TRON attractive to legitimate users — low fees, lack of volatility, and ease of use — have also drawn the attention of scammers, terrorist financiers, and other threat actors. And as the TRON blockchain's popularity and user base grow, drawn by its high throughput and low transaction costs, so too does its uninvited exposure to these criminal elements. The establishment of the T3 FCU represents a significant step towards impeding the ability of malicious actors to launder and utilize the proceeds of crime, safeguarding the integrity of the TRON blockchain. As part of the collaboration, TRM will provide ongoing support to TRON and Tether in identifying transactions that have a connection to alleged illegal activities such as terrorism, sanctions evasion, theft, hacking, cybercrime, and fraud. TRM will leverage its proprietary technology as well as its global network of expert investigators to generate intelligence. The work will support TRON’s and Tether’s efforts to disrupt criminal activity and aid collaborations with law enforcement around the world. By collaborating to proactively identify and disrupt illicit activity, the T3 FCU aims to promote security and prosperity across the TRON network and beyond. “TRON originated with the belief that technology can be used for good and to empower people across the globe,” said Justin Sun, founder of the TRON blockchain. “By collaborating with TRM Labs and Tether, TRON is helping to ensure that blockchain technology is used to make our world a better place, and sends a clear message that illicit activity is not welcome in our industry.” "At Tether, safeguarding the integrity of the blockchain ecosystem is a top priority and a responsibility we embrace with being a key player in the digital asset space. This commitment drives us to take proactive measures in helping maintain the security and trustworthiness of the ecosystem," said Paolo Ardoino, CEO of Tether. "We’re proud to have worked with TRM Labs and TRON in this pioneering effort. This collaboration underscores our dedication to joining with industry leaders and law enforcement to combat illicit activity, ensuring a secure environment for all users." “As adoption of stablecoins continues to rise, it’s critical that key industry players proactively evolve their capabilities to combat illicit activity and ensure a safe and secure environment,” said Chris Janczewski, head of global investigations at TRM Labs. “TRM is proud to collaborate with TRON, Tether, law enforcement, and others who are committed to helping build a safer blockchain industry for all.” About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by Justin Sun, the TRON network has continued to deliver impressive achievements since MainNet launch in May 2018. July 2018 also marked the integration of BitTorrent, a pioneer in decentralized Web3 services, boasting over 100 million monthly active users. The TRON network has gained incredible traction in recent years. As of August 2024, it has over 247 million total user accounts on the blockchain, more than 8 billion total transactions, and over $22 billion in total value locked (TVL), as reported on TRONSCAN. In addition, TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin across the globe, overtaking USDT on Ethereum since April 2021. The TRON network completed full decentralization in December 2021 and is now a community-governed DAO. Media contact: press@tron.network About Tether Tether is a pioneer in the field of stablecoin technology, driven by an aim to revolutionize the global financial landscape. With a mission to provide accessible and efficient financial, communication, artificial intelligence and energy infrastructure. Tether enables greater financial inclusion, and communication resilience, fosters economic growth, and empowers individuals and businesses alike. As the creator of the largest, most transparent, and liquid stablecoin in the industry, Tether is dedicated to building sustainable and resilient infrastructure for the benefit of underserved communities. By leveraging cutting-edge blockchain and peer-to-peer technology, it is committed to bridging the gap between traditional financial systems and the potential of decentralized finance. Media contact: press@tether.to About TRM Labs TRM Labs provides blockchain intelligence to help law enforcement and national security agencies, financial institutions, and cryptocurrency businesses detect, investigate, and disrupt crypto-related fraud and financial crime. TRM’s Blockchain Intelligence platform includes solutions to follow the money, identify illicit activity, build cases, and construct an operating picture of threats. TRM is trusted by a growing number of leading agencies worldwide who rely on TRM for their blockchain intelligence needs. TRM is based in San Francisco, CA, and is hiring across engineering, product, sales, and data science. To learn more, visit www.trmlabs.com. Media contact: press@trmlabs.com Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

September 10, 2024 10:15 AM Eastern Daylight Time

Image

PathAI Launches MET Predict on AISight to Enhance NSCLC Assessments

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict † on the AISight Ⓡ † Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image. NSCLC accounts for approximately 85% of lung cancers 1, with 3–4% of these cases involving METex14 2. Today, approved targeted therapies are available for patients with NSCLC who harbor METex14 mutations. Additionally, MET amplification occurs in 1–6% of NSCLC cases 3 and is emerging as a potential biomarker in lung cancer. Traditional molecular testing for MET alterations such as exon 14 skipping or amplification is often hindered by high costs, time- and tissue-consuming procedures, and the need for specialized equipment and trained personnel. These factors limit its accessibility and scalability, prompting the need for more efficient and cost-effective methods to assess MET alterations. “The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By providing rapid and precise biomarker insights directly from H&E images, MET Predict equips pathologists with the essential information needed to drive timely and accurate NSCLC evaluations.” MET Predict has the potential to significantly improve the efficiency of biomarker evaluation and molecular testing paradigms. The algorithm identifies >90% of MET altered tumors while additionally providing insights that may preserve tissue in 30% of cases where the likelihood of MET alteration is low. With the addition of MET Predict, AISight expands its toolset with the latest technology to assist pathologists in lung cancer assessments. This innovation addresses a crucial gap in pathology labs — the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. †:MET Predict and AISight are for Research Use Only. Not for use in diagnostic procedures. References: 1 American Cancer Society. Key Statistics for Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/what-is.html 2 Frampton, G. M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer discovery, 5(8), 850-859. 3 Wolf J., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PMID: 32877583 About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions, dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 10, 2024 10:00 AM Eastern Daylight Time

Image

Brand Engagement Network (NASDAQ: BNAI) Expands Global Footprint As It Secures $5.9M in Private Placement Financing And Enters $50M Standby Equity Purchase Agreement

Benzinga

By Anthony Termini, Benzinga Brand Engagement Network (NASDAQ: BNAI) (BEN), which creates artificial intelligence (AI) solutions for consumer engagement using human-like avatars as the interface to communicate with customers, hit multiple milestones recently Early in September, the company entered into an agreement with IntelliTek Health. IntelliTek Health is a subsidiary of SmarTek21 and creates solutions for virtual assistants that interact with medical patients. It develops clinical and patient-facing tools and focuses exclusively on bringing AI-enabled productivity and services to the healthcare industry. What The IntelliTek Deal Means For BEN The agreement grants BEN a worldwide license to provide AI-driven solutions to support healthcare operations and optimize patient engagement throughout the United States, Australia, New Zealand, India and Europe. Together, BEN and IntelliTek will offer a suite of AI-driven healthcare solutions to support and execute a broad range of tasks and operations that serve both medical professionals and patients. The agreement is intended to seek synergies in the strengths and solutions of both companies. Brand Engagement Network will combine its Healthcare AI Assistant, Sandy – which serves as a direct interface resource for patients – with IntelliTek’s Personal Virtual Assistant (PVA). Sandy can help patients schedule appointments and obtain up-to-date information on prescription drugs. The IntelliTek PVA is part of a collaboration with Samsung Mobile Solutions and other leading U.S. and multinational telecommunications companies. The deal also combines BEN’s AI technology with IntelliTek’s Clinical Virtual Assistant (CVA). The CVA is specifically designed for clinical teams looking to reduce their administrative burden. BEN reports that it has been shown to improve administrative efficiency by up to 50%, creating the opportunity to improve patient throughput by up to 17%. Another solution rolled into the agreement is IntelliTek’s hands-free and voice-enabled Document Search AI. This device-agnostic tool can quickly and securely search for and retrieve specific medical information in real time from many different document formats sourced from a wide variety of different repositories. Martyn Molnar, Chief Executive of Products at Intellitek Health, says that the “cooperation with BEN will enable both companies to offer a comprehensive suite of AI solutions for the healthcare industry, which is experiencing critical challenges surrounding workforce and resource availability.” “We’re proud to have found a like-minded ally in IntelliTek, as we both strive to elevate patient experiences and healthcare professional productivity with innovative AI technology,” added Paul Chang, BEN’s CEO. The two executives believe that together the platforms can serve as an end-to-end suite of solutions that offers continuous support to improve healthcare access and outcomes. They believe the collaboration will help each company broaden its customer base. It is expected that the agreement will expand the reach of both companies’ solutions to a larger number of healthcare providers and patients and increase access to life-saving AI technology. IntelliTek delivers highly curated products that automate over 2 billion interactions reaching more than 600 million global users, reports the company. The company and its parent, SmarTek21, ensure seamless connectivity of more than 100 pre-built integrations to support AI-driven solutions. Together they provide intelligent workflow automation across healthcare, telecommunications, aviation, finance and global eCommerce platforms. The healthcare industry represents one of BEN’s primary target markets. The company’s full-stack platform includes front-end, middleware and back-end functionality through scalable, customizable solutions that it says are fully optimized to deliver superior customer experiences, productivity and performance. New Financing Transactions Prior to the IntelliTek Health announcement, BEN completed two investment transactions that provide the company with increased financial flexibility and access to capital to support its ongoing strategic growth initiatives. In August, BEN closed a $5.9 million private placement, which will provide funding to the company on a monthly basis through the first quarter of 2025. The investment was supported by a group of BEN’s existing stockholders, who agreed to purchase nearly 1.2 million shares of common stock. The transaction was consummated at a price per share that was materially above the trading price of the company’s common stock at the time. For each share purchased, investors received an additional share of common stock from certain other existing stockholders. In exchange for transferring those shares, certain transferring stockholders received an aggregate of 960,000 warrants to purchase shares of BEN’s common stock at $5.00 per share. Concurrent with the private placement, BEN also entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The SEPA provides BEN with the ability, but not the obligation, to cause Yorkville to purchase up to the aggregate amount of $50 million of BEN common stock. The SEPA is intended to provide BEN with access to capital on an as-needed basis to fund its business plan as it seeks to execute its growth and revenue strategies. The SEPA cannot be used until a registration statement is declared effective by the Securities and Exchange Commission. These two transactions are intended to help the company expand market validation and scale production of its human-like conversational AI assistants. For more information about BEN, please visit www.beninc.ai. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:55 AM Eastern Daylight Time

Image

Syntekabio Appoints Joonhyuk Choi, Former Target Health CEO, as Head of US Operations

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce the appointment of Joonhyuk Choi, former CEO of Target Health, as Head of US Operations. Joonhyuk brings over 25 years of extensive experience in the pharmaceutical industry, underpinned by his academic background in electrical and computer engineering from Rutgers University in New Jersey. His prominent career is distinguished by a strong track record in developing clinical trial software, navigating the US FDA’s drug and medical device approval processes, managing clinical trials, and leading business development success. Prior to joining Syntekabio, Joonhyuk served as CEO of Target Health, a US-based contract research organization (CRO). There, he played a pivotal role in clinical operations and drove business development, spearheading sales and marketing teams while overseeing the development and maintenance of validated software solutions for clinical trials and data management for over two decades. Syntekabio anticipates that Joonhyuk, with his deep understanding of the drug development process from AI-driven drug discovery and clinical trials to drug approvals as well as business development, coupled with his extensive knowledge of the US market, will significantly enhance the company’s strategic partnership and revenue-generating initiatives. “I am honored to join Syntekabio at such a pivotal moment in the company’s journey,” said Joonhyuk Choi, newly appointed Head of US Operations. “I am committed to leveraging strategies tailored to the unique dynamics of the US pharma and biotech market to enhance the global reach and impact of Syntekabio’s AI drug discovery platform.” Jongsun Jung, PhD, CEO of Syntekabio, remarked, “With Joonhyuk’s appointment, Syntekabio is now strategically positioned to collaborate with potential partners across the entire drug development spectrum, from AI-driven candidate screening to clinical trials. His extensive expertise and experience in the US market will be crucial in driving our global expansion and enhancing our competitiveness, positioning us for achieving sustained business success.” About SyntekabioSyntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries – US & Europe - Laurie Doyle MC Services AG +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 10, 2024 08:00 AM Eastern Daylight Time

Flash Secures $85 Million to Back Special Purpose Vehicle to Propel Growth and Provide Flexible Payment Options

Flash

Flash, the industry-leading end-to-end parking technology platform, today announced that it has closed on $85 million in debt financing for a newly formed special purpose vehicle (“SPV”) to accelerate platform adoption and offer Flash clients an expanded range of flexible payment options. The debt capital, which can be increased up to $100 million, was provided by Vantage Infrastructure (“Vantage”), a leading independent specialist infrastructure credit fund. “Asset owners and operators have a myriad of budgetary and deployment preferences – the payment options we can now extend through the SPV will allow customers to join the Flash platform on terms that work best for them," said Chris Donus, President of Flash. “Innovation in payment options is as critical as platform innovation in pursuit of our vision for the parking industry’s transformation in light of the scale and momentum we're on pace to achieve." Flash’s payment options allow clients to select amongst flexible monthly payment plans that suit their budgets, regardless of scale, asset type, or configuration. This includes EV charging infrastructure and other advanced parking technologies offered by Flash. Flash anticipates extending the SPV structure and partnership with Vantage in future financings. ”We’re pleased to support Flash with a tailored financing solution that enables their team to continue to meet and exceed their clients’ need for better transport related infrastructure,” said Nick Cleary, Senior Partner at Vantage. “This is a great example of the opportunity to upgrade and transform proven traditional infrastructure that saves time and costs for drivers and help build out the EV charging network.” Evercore acted as Flash’s exclusive financial advisor, and Cadwalader, Wickersham & Taft LLP provided legal counsel to Flash. Steptoe LLP acted as counsel to Vantage. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. About Vantage Infrastructure Vantage Infrastructure is an independent infrastructure specialist manager committed to delivering sustainable investment solutions with an equity and debt infrastructure investment portfolio of over US $4 billion invested in infrastructure assets across Europe, North America, and Australia on behalf of global clients. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 09, 2024 09:00 AM Central Daylight Time

Syntekabio to Highlight its Cutting-edge AI-driven Discovery Solutions at BioTechX

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, today announced its participation at BioTechX USA, being held September 17-18, 2024 in Philadelphia, PA. Syntekabio is the Title Sponsor for the event and will give a keynote address and in-depth talk on its AI-driven solutions, as well as host a booth. “We look forward to meeting with potential clients at BioTechX and discussing how our AI-driven technologies can improve and accelerate their R&D activities,” said Jongsun Jung, PhD, CEO of Syntekabio. “We recently announced our ‘Develop Now, Pay Later’ offer that enables clients to test the validity of a target protein of interest without incurring any upfront costs. In addition to identifying potential hits and optimizing small molecule leads, we also have strong capabilities in antibody and cancer neoantigen discovery. We are excited to have the opportunity to highlight these technologies at the conference.” Meet us at BioTechX USA! Syntekabio has several activities planned at the conference. Schedule a meeting by clicking here or stop by our booth (#401) to meet the team and learn how our innovative AI-driven solutions can help solve your current pipeline challenges. Don’t miss out on the latest insights in AI presented in our talks! Tuesday, September 17 th 9:20 AM - Keynote presentation Addressing Data Scarcity in D rug Discovery with Physics-based AI Models Jonathan Witztum, PhD, CTO, Syntekabio USA 5:05 PM – AI in drug discovery presentation Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application Jongsun Jung, PhD, CEO, Syntekabio Recently announced Develop Now, Pay Later offer – drug discovery with no upfront fees Syntekabio’s Develop Now, Pay Later model enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs. Should a project demonstrate viability, Syntekabio then employs its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher ® technology platform, to deliver hits and optimized leads as well as IND-enabled candidates. The client only pays for the work once the agreed upon validated results are obtained. For more information about Syntekabio, STB LaunchPad and Develop Now, Pay Later, please click here. Additional powerful tools enable novel antibody and cancer neoantigen prediction Additionally, the company will highlight its in silico biologics platforms, Neo-ARS TM and Ab-ARS TM, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively. These cutting-edge solutions address complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics. Syntekabio’s AI accesses over 10 billion known compounds as well as 1,400 in vitro/in vivo compatible drug targets covering over 70% of human diseases. This technology is powered by Syntekabio’s AI Bio-Supercom Center, which houses an immense infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs fueling the Company’s algorithms. The Company has a comprehensive suite of advanced proprietary tools designed to accelerate the drug discovery and development process. About Syntekabio Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries US & Europe - MC Services AG Laurie Doyle / Dr. Cora Kaiser +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 06, 2024 08:30 AM Eastern Daylight Time

PayMedix/TempoPay Names David Kinsey Vice President of Sales

PayMedix/TempoPay

PayMedix/TempoPay announced today the appointment of David Kinsey as Vice President of Sales. Kinsey joins during a period of accelerated growth for PayMedix/TempoPay, which delivers innovative healthcare payment solutions that provide interest-free financing to employees for healthcare services, no matter their credit histories. Kinsey brings an extensive background in the healthcare and employee benefits industry. In his new role, Kinsey will lead sales initiatives, focused on driving growth of the PayMedix/TempoPay solution and building strategic relationships across the healthcare industry with a specific focus on the Southeast region. “As more health systems, employers, and benefits administrators across the country continue to look for ways to lower costs and provide affordable access to healthcare for employees, we're seeing increased interest in our flexible financing and payments solutions," said Tom Policelli, CEO of PayMedix/TempoPay. "David's extensive knowledge of healthcare sales and the employee benefits industry will help us increase our reach and ability to serve providers and employers looking for alternative healthcare payment solutions. We are excited to welcome him to our team." Before his current role, Kinsey was an Executive Director at Aetna. He led the Healthcare Business Solutions team to achieve 60% growth over five years by directing enterprise sales, retention, and membership growth strategy. Kinsey was awarded Aetna's Chairman's Leadership Award for his leadership and collaboration. Kinsey’s prior roles at Aetna included working with employer groups and consultants on innovative employee benefits strategies and plan administration. Prior to Aetna, he was a Senior Client Manager at Cigna Healthcare, where he was awarded the Gold Circle for top sales results. He earned his BBA in Finance from Stetson University. "The PayMedix/TempoPay solution is a game-changer, offering a straightforward and effective approach to tackling the demanding issue of high out-of-pocket healthcare costs," said Kinsey. "I look forward to working with the team to expand our reach and bring employers a financial safety net for their employees that ultimately improves retention and reduces absenteeism.” “Having worked with David previously, I am confident in his ability to help employers, PEOs, health plans and network builders see the value in our solution,” said Brian Marsella, President, PayMedix/TempoPay. “By ensuring individuals have access to financial resources to get care when they need versus when they think they can afford it, we can break the cycle of care avoidance, which historically has led to sicker patients entering the system, worse outcomes and increased costs.” About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With the TempoPay VisaÂ® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. Contact Details Brodeur Partners Sam LeCompte +1 603-660-9407 slecompte@brodeur.com Company Website https://paymedix.com

September 05, 2024 10:00 AM Eastern Daylight Time

1 ... 21 22 23 24 25 ... 639